Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017

Summary

”Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017”, a new report by Global Markets Direct, provides key market data on the Greece In Vitro Diagnostics market. The report provides value (USD million), for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on key recent developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct’s team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
- Annualized market revenues (USD million) for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
- 2010 company shares and distribution shares data for each of the seven market categories.
- Global corporate-level profiles of key companies operating within the Greece In Vitro Diagnostics market.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Greece In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What is This Report About?
3 In Vitro Diagnostics In Greece
3.1 In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, 2003-2017
3.2 In Vitro Diagnostics, Greece, Company share (2009-2010)
4 Clinical Chemistry In Greece
4.1 Clinical Chemistry Overall Revenue (2003-2017)
4.1.1 Clinical Chemisty Analyzers Revenue (2003-2017)
4.1.2 Urine Analysis Revenue (2003-2017)
4.2 Clinical Chemistry Distribution Share (2009-2010)
4.3 Clinical Chemistry, Greece, Company share (2009-2010)
5 Genetic Testing In Greece
5.1 Genetic Testing Overall Revenue (2003-2017)
5.2 Genetic Testing Distribution Share (2009-2010)
5.3 Genetic Testing, Greece, Company share (2009-2010)
6 Haematology In Greece
6.1 Haematology Overall Revenue (2003-2017)
6.1.1 Haematology Reagents Revenue (2003-2017)
6.1.2 Immunohaematology Revenue (2003-2017)
6.1.3 Haemostasis Revenue (2003-2017)
6.1.4 Haematology Rapid Tests Revenue (2003-2017)
6.1.5 Haematology Cell Counters Revenue (2003-2017)
6.2 Haematology Distribution Share (2009-2010)
6.3 Haematology, Greece, Company share (2009-2010)
7 Histology And Cytology In Greece
7.1 Histology And Cytology Overall Revenue (2003-2017)
7.2 Histology And Cytology Distribution Share (2009-2010)
7.3 Histology And Cytology, Greece, Company share (2009-2010)
8 Immuno Chemistry In Greece
8.1 Immuno Chemistry Overall Revenue (2003-2017)
8.1.1 Disease Specific Immunochemistry Revenue (2003-2017)
8.1.2 Drugs of Abuse / Toxicology Revenue (2003-2017)
8.1.3 Endocrinology Tests Revenue (2003-2017)
8.1.4 Therapeutic Drug Monitoring Revenue (2003-2017)
8.1.5 Immunochemistry Analyzers Revenue (2003-2017)
8.2 Immuno Chemistry Distribution Share (2009-2010)
8.3 Immuno Chemistry, Greece, Company share (2009-2010)
9 Infectious Immunology In Greece
9.1 Infectious Immunology Overall Revenue (2003-2017)
9.2 Infectious Immunology Distribution Share (2009-2010)
9.3 Infectious Immunology, Greece, Company share (2009-2010)
10 Microbiology Culture In Greece
10.1 Microbiology Culture Overall Revenue (2003-2017)
10.1.1 Microbiology Analyzers Revenue (2003-2017)
10.2 Microbiology Culture Distribution Share (2009-2010)
10.3 Microbiology Culture, Greece, Company share (2009-2010)
11 Overview of Key Companies in Greece In Vitro Diagnostics Market
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 Company Overview
11.2 Siemens Healthcare
11.2.1 Company Overview
11.3 Abbott Laboratories
11.3.1 Company Overview
11.4 Beckman Coulter, Inc.
11.4.1 Company Overview
11.5 Ortho-Clinical Diagnostics Inc.
11.5.1 Company Overview
11.6 bioMerieux S.A.
11.6.1 Company Overview
11.7 Sysmex Corporation
11.7.1 Company Overview
11.8 Bio-Rad Laboratories, Inc.
11.8.1 Company Overview
11.9 Becton, Dickinson and Company
11.9.1 Company Overview
11.10 Phadia AB
11.10.1 Company Overview
11.11 DiaSorin S.p.A
11.11.1 Company Overview
11.12 DIAGNOSTICA STAGO, Inc.
11.12.1 Company Overview
11.13 PerkinElmer, Inc.
11.13.1 Company Overview
11.14 Thermo Fisher Scientific Inc.
11.14.1 Company Overview
11.15 Qiagen N.V.
11.15.1 Company Overview
11.16 Grifols, S.A.
11.16.1 Company Overview
11.17 HORIBA, Ltd.
11.17.1 Company Overview
11.18 Gen-Probe Incorporated
11.18.1 Company Overview
11.19 Immucor, Inc.
11.19.1 Company Overview
11.20 Life Technologies Corporation
11.20.1 Company Overview
11.21 Danaher Corporation
11.21.1 Company Overview
11.22 Hologic, Inc.
11.22.1 Company Overview
11.23 Cellestis Limited
11.23.1 Company Overview
12 Financial Deals Landscape
12.1 Partnerships
12.1.1 Biofortuna Enters Into Distribution Agreement With Abbott
12.1.2 Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics
13 APPENDIX
13.1 Global Markets Direct Research Methodology
13.2 Definitions of Markets Covered in the Report
13.2.1 In Vitro Diagnostics
13.3 Secondary Research
13.4 Primary Research
13.5 Models
13.6 Forecasts
13.7 Expert Panel Validation
13.8 Currency Conversion
13.9 Contact Us
13.10 Disclaimer

1.1 List of Tables
Table 1: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, 2003-2017
Table 2: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Table 3: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Table 4: In Vitro Diagnostics, Greece, Company share by Revenue ($m), USD Actual, 2009-2010
Table 5: Clinical Chemistry, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 6: Clinical Chemistry, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 7: Clinical Chemisty Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 8: Clinical Chemisty Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 9: Urine Analysis, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 10: Urine Analysis, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 11: Clinical Chemistry, Greece, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 12: Clinical Chemistry, Greece, Company share by Revenue ($m), USD Actual 2009-2010
Table 13: Genetic Testing, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 14: Genetic Testing, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 15: Genetic Testing, Greece, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 16: Genetic Testing, Greece, Company share by Revenue ($m), USD Actual 2009-2010
Table 17: Haematology, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 18: Haematology, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 19: Haematology Reagents, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 20: Haematology Reagents, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 21: Immunohaematology, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 22: Immunohaematology, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 23: Haemostasis, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 24: Haemostasis, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 25: Haematology Rapid Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 26: Haematology Rapid Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 27: Haematology Cell Counters, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 28: Haematology Cell Counters, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 29: Haematology, Greece, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 30: Haematology, Greece, Company share by Revenue ($m), USD Actual 2009-2010
Table 31: Histology And Cytology, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 32: Histology And Cytology, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 33: Histology And Cytology, Greece, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 34: Histology And Cytology, Greece, Company share by Revenue ($m), USD Actual 2009-2010
Table 35: Immuno Chemistry, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 36: Immuno Chemistry, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 37: Disease Specific Immunochemistry, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 38: Disease Specific Immunochemistry, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 39: Drugs of Abuse / Toxicology, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 40: Drugs of Abuse / Toxicology, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 41: Endocrinology Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 42: Endocrinology Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 43: Therapeutic Drug Monitoring, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 44: Therapeutic Drug Monitoring, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 45: Immunochemistry Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 46: Immunochemistry Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 47: Immuno Chemistry, Greece, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 48: Immuno Chemistry, Greece, Company share by Revenue ($m), USD Actual 2009-2010
Table 49: Infectious Immunology, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 50: Infectious Immunology, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 51: Infectious Immunology, Greece, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 52: Infectious Immunology, Greece, Company share by Revenue ($m), USD Actual 2009-2010
Table 53: Microbiology Culture, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 54: Microbiology Culture, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 55: Microbiology Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 56: Microbiology Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 57: Microbiology Culture, Greece, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 58: Microbiology Culture, Greece, Company share by Revenue ($m), USD Actual 2009-2010
Table 59: Biofortuna Enters Into Distribution Agreement With Abbott
Table 60: Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics
Table 61: USD to Local Currency, Greece, Average Actual Rate 2003-2010

1.2 List of Figures
Figure 1: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, 2003-2017
Figure 2: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Figure 3: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Figure 4: In Vitro Diagnostics, Greece, Company share (%), 2010
Figure 5: Clinical Chemistry, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 6: Clinical Chemistry, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 7: Clinical Chemisty Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 8: Clinical Chemisty Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 9: Urine Analysis, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 10: Urine Analysis, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 11: Clinical Chemistry, Greece, Company share (%), 2010
Figure 12: Genetic Testing, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 13: Genetic Testing, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 14: Genetic Testing, Greece, Company share (%), 2010
Figure 15: Haematology, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 16: Haematology, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 17: Haematology Reagents, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 18: Haematology Reagents, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 19: Immunohaematology, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 20: Immunohaematology, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 21: Haemostasis, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 22: Haemostasis, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 23: Haematology Rapid Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 24: Haematology Rapid Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 25: Haematology Cell Counters, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 26: Haematology Cell Counters, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 27: Haematology, Greece, Company share (%), 2010
Figure 28: Histology And Cytology, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 29: Histology And Cytology, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 30: Histology And Cytology, Greece, Company share (%), 2010
Figure 31: Immuno Chemistry, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 32: Immuno Chemistry, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 33: Disease Specific Immunochemistry, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 34: Disease Specific Immunochemistry, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 35: Drugs of Abuse / Toxicology, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 36: Drugs of Abuse / Toxicology, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 37: Endocrinology Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 38: Endocrinology Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 39: Therapeutic Drug Monitoring, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 40: Therapeutic Drug Monitoring, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 41: Immunochemistry Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 42: Immunochemistry Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 43: Immuno Chemistry, Greece, Company share (%), 2010
Figure 44: Infectious Immunology, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 45: Infectious Immunology, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 46: Infectious Immunology, Greece, Company share (%), 2010
Figure 47: Microbiology Culture, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 48: Microbiology Culture, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 49: Microbiology Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 50: Microbiology Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 51: Microbiology Culture, Greece, Company share (%), 2010
Figure 52: Global Markets Direct Methodology

F. Hoffmann-La Roche Ltd.
Siemens Healthcare
Abbott Laboratories
Beckman Coulter, Inc.
Ortho-Clinical Diagnostics Inc.
bioMerieux S.A.
Sysmex Corporation
Bio-Rad Laboratories, Inc.
Becton, Dickinson and Company
Phadia AB
DiaSorin S.p.A
DIAGNOSTICA STAGO, Inc.
PerkinElmer, Inc.
Thermo Fisher Scientific Inc.
Qiagen N.V.
Grifols, S.A.
HORIBA, Ltd.
Gen-Probe Incorporated
Immucor, Inc.
Life Technologies Corporation
Danaher Corporation
Hologic, Inc.
Cellestis Limited

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.